Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms, Castration-Resistant 1 Prostatic Neoplasms 1

Interventions

enzalutamide 16 Magnetic Resonance Spectroscopy 16 apalutamide 15 Prednisone 12 Androgen Antagonists 12 Abiraterone Acetate 12 Specimen Handling 11 darolutamide 7 abiraterone 7 Radiotherapy 7 Pluvicto 6 Nivolumab 6 Docetaxel 6 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 6 cabazitaxel 5 Radiosurgery 5 Lutetium-177 5 Biopsy 5 radium Ra 223 dichloride 4 cabozantinib 4 bicalutamide 4 atezolizumab 4 Standard of Care 4 Lutetium 4 olaparib 3 gallium 68 PSMA-11 3 Watchful Waiting 3 Surveys and Questionnaires 3 Radiotherapy, Intensity-Modulated 3 Fulvestrant 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Prostatic Neoplasms × fludrocortisone acetate × 30 days × Clear all

NCT06136650 2026-06-03

MK-5684-004

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡